Corey Nislow's laboratory develops and uses cutting edge tools to address this central question: how can we understand the biological commonalities in all of the life sciences; from embryonic development, to the spread of infectious diseases to better ways to treat cancer. Each of these disciplines can be explained in the context of competition, interaction and evolution. His lab studies the interface between genes and the environment using parallel genome-wide screens, high throughput cell-based assays and next generation sequencing. Most recently, he and his scientific partner, Dr. Guri Giaever, are exploring how laboratory experiments can co-opt evolutionary processes to understand drug action. He enjoys teaching all aspects of biotechnology, genomics and drug discovery. He got his PhD from the University of Colorado, worked at several Biotechnology companies and was at Stanford and University of Toronto before joining UBC in 2013. He has published 161 papers and run 19 marathons.
Associate scientist and professor of epigenomics and bioinformatics at the department of neurosurgery and genetics.
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
I obtained my PhD from the Institute of Cancer Research in London spent a further 10 years there as a postdoctoral fellow and Staff Scientist. I am currently a Lecturer in Molecular Biology at the University of Stirling in Scotland. My principal research interest is translational oncology, with a focus on epigenetics.
Douglas Pires is a Senior Lecturer in Digital Health in the School of Computing and Information Systems at the University of Melbourne. Previously, he was a group leader and researcher in public health at Oswaldo Cruz Foundation/Brazil. He was also a postdoctoral researcher fellow at the University of Cambridge and University of Melbourne. He received a PhD in Bioinformatics from the Universidade Federal de Minas Gerais/Brazil and a BSc in Computer Science, both with highest honours, by the same university. His research interests include: Computational Biology, Translational Bioinformtaics and Machine Learning.
I am a Computational Biologist, Assistant Professor at Weill Medical College of Cornell University. I use -omic data to understand the mechanisms of disease risk.
I began my career as a Biology Undergraduate at MIT, where my first research project was to invent a method for attaching DNA to glass as part of the then-unfinished Human Genome Project. After MIT, I explored career options in Medical School Sillicon Valley and NIH, eventually earning a PhD in Bioinformatics and Systems Biology from UCSD. My doctoral dissertation involved characterizing the regulatory genetics of the adrenaline-synthesis gene PNMT, as well as more broadly studying the human adrenergic stress pathway. Seeking additional training in genomics and statistics, I spent a year working with Kelly Frazer at the Moores UCSD Cancer Center, followed by a move to Weill Cornell Medical College in 2010. As a postdoc, I developed a set of genomic analysis skills and tools that I applied to numerous projects, both locally and with international collaborators such as the 1000 Genomes Project, Weill Cornell Medical School in Qatar, and the University of Puerto Rico. In my current appointment as Assistant Professor, I am tasked with developing biotechnology tools for precision medicine.
I am a Professor at the University of Santiago de Compostela (Galicia, Spain). During the last few years I have been investigating in various fields of biomedical research, such as the analysis of genetic susceptibility to complex and common diseases (breast cancer, schizophrenia, autism, etc.), rare diseases (Wilson's disease, congenital ichthyosis, mitochondriopathies, etc.), bioinformatics / biostatistics (regarding HapMap, 1000 Genomes, statistical procedures in epidemiology and genetics, etc.), molecular / archeo-genetic anthropology, and forensic genetics (population sub-structure, interpretation (statistics) of the test Medical-legal research haplotype markers, etc).
I am the head of a consolidated research group, GenPoB (Population Genetics in Biomedicine), based at the Health Research Institute (IDIS) of Santiago de Compostela (Galicia, Spain), that is in turn integrated into the Genetics and Systems Biology group.
For more than a decade I have been heavily involved in a variety of projects related to genomics and other fields of -omic ’sciences (e.g. transcriptomic, epigenomic), in complex pediatric diseases, infectology and vaccinomics.
Dr. Yuan Shang works on Alzheimer's Disease (AD) at the University of Arizona. He combines any potential methods and data to search potential therapeutic opportunities for AD. He is an expert on omics data analysis, multi-omics integrations, network-based pattern recognition, and machine learning-based biomarker discoveries.
Dr. Singh received his B.Sc. from the Government Degree College Nahan, H.P. University, India and his M.Sc. and Ph.D from Devi Ahilya University, Indore, India. After a short stint as a Research Associate in the field of Trangenics of silkworm, Bombyx mori, in Indian Institute of Sciences (IISc.), Bangalore, India, Dr. Singh moved to Academic Sinica Taiwan to pursue post doctoral research in the field of eye development using Drosophila melanogaster model system. In 2002, Dr. Singh moved to Baylor College of Medicine, Houston, Texas to further pursue his work on Drosophila eye development and was promoted to an instructor (non-tenure track faculty) position in 2004. Dr. Singh was hired at University of Dayton as a tenure track assistant professor in 2007 and promoted to associate professor in 2013. To date, he has published one book and 52 papers.
Kumar Somasundaram is a Professor at Department of Microbiology Cell Biology, Indian Institute of Science, Bangalore, India. He obtained his Veterinary Medicine degree (1985) from Madras Veterinary College, Masters in Biotechnology (1987) and Ph.D. in bacterial genetics (1993) from Madurai Kamaraj University, Madurai, India. Subsequently, he did his post-doctoral training at Northwestern University and University of Pennsylvania in Cancer Biology before moving to Indian Institute of Science (1999) as a faculty. The major focus of his laboratory is genetics of glioma, the most common primary adult cancer
Professor of Genetic Epidemiology at the Medical Faculty and Director of the Leibniz-Institute for Arteriosclerosis Research at the University of Muenster, Germany. Former Associate Editor of Physiological Genomics, Academic Editor of PLoS ONE. Main research interests: Genetics of complex disease traits, in particular cardiovascular and inflammatory diseases; comparative genomics, evolutionary medicine.
Assistant Professor Departments of Cancer Biology and Genetics and Surgery, The Ohio State University
We are interested in mechanisms of autophagy regulation, with a focus on discovering how to modulate the pathway for optimal therapeutic benefit. Current projects are focused on the identification of novel autophagy regulators and their functional relevance for lung tumorigenesis